Published in Cryobiology on August 01, 2003
Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol (2007) 1.75
Loss of T cell responses following long-term cryopreservation. J Immunol Methods (2007) 1.23
Cryopreservation: An emerging paradigm change. Organogenesis (2009) 0.95
The roles of apoptotic pathways in the low recovery rate after cryopreservation of dissociated human embryonic stem cells. Biotechnol Prog (2010) 0.91
The individual-cell-based cryo-chip for the cryopreservation, manipulation and observation of spatially identifiable cells. II: functional activity of cryopreserved cells. BMC Cell Biol (2010) 0.75
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med (2008) 5.71
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J Immunol (2007) 2.04
De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother (2005) 1.70
Budding of equine infectious anemia virus is insensitive to proteasome inhibitors. J Virol (2002) 1.67
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol (2002) 1.60
Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol (2004) 1.57
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem (2008) 1.49
Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater (2010) 1.47
Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. Virology (2005) 1.38
Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol (2004) 1.31
Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis (2007) 1.28
Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother (2005) 1.27
Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet Res (2004) 1.26
The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles. J Virol (2010) 1.25
Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious anemia virus budding. J Biol Chem (2005) 1.24
Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J Virol (2005) 1.22
Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS. J Infect Dis (2010) 1.19
Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. J Virol (2013) 1.18
Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J Virol (2005) 1.14
Differential effects of actin cytoskeleton dynamics on equine infectious anemia virus particle production. J Virol (2004) 1.14
A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus. Proc Natl Acad Sci U S A (2005) 1.14
De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother (2007) 1.10
HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking. PLoS One (2009) 1.04
Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway. J Virol (2005) 1.04
Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother (2013) 1.03
Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol (2002) 1.03
Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides (2003) 1.01
Comparison of the effects of pathogenic simian human immunodeficiency virus strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques. AIDS Res Hum Retroviruses (2008) 1.01
Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res (2007) 1.01
Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A (2007) 1.00
Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. J Antimicrob Chemother (2011) 0.99
Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun (2010) 0.99
Expression of IFN-gamma induced CXCR3 agonist chemokines and compartmentalization of CXCR3+ cells in the periphery and lymph nodes of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. J Med Primatol (2003) 0.96
Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr (2005) 0.96
MicroRNA-17~92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood (2013) 0.95
Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine (2006) 0.95
Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol (2002) 0.94
Association of gag multimers with filamentous actin during equine infectious anemia virus assembly. Curr HIV Res (2007) 0.93
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One (2010) 0.93
Early CD8 T-cell memory precursors and terminal effectors exhibit equipotent in vivo degranulation. Cell Mol Immunol (2014) 0.93
Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 0.92
Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication. J Biol Chem (2011) 0.92
Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol (2008) 0.91
Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol (2005) 0.90
Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles. Virol J (2010) 0.89
EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr HIV Res (2010) 0.89
Evaluation of cervical mucosa in transmission bottleneck during acute HIV-1 infection using a cervical tissue-based organ culture. PLoS One (2012) 0.89
Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol (2007) 0.87
Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses. Clin Diagn Lab Immunol (2004) 0.87
Budding of retroviruses utilizing divergent L domains requires nucleocapsid. J Virol (2012) 0.86
Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope. J Immunol (2002) 0.86
Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology (2005) 0.86
Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain. Virology (2007) 0.86
Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides. Virology (2003) 0.86
Lentivirus lytic peptide 1 perturbs both outer and inner membranes of Serratia marcescens. Antimicrob Agents Chemother (2002) 0.86
Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses (2013) 0.86
Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis. Int J Antimicrob Agents (2012) 0.85
Efficacy of the de novo-derived antimicrobial peptide WLBU2 against oral bacteria. Antimicrob Agents Chemother (2007) 0.84
Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine (2010) 0.84
Antimicrobial peptides: new drugs for bad bugs? Expert Opin Biol Ther (2013) 0.84
Effect of Symplocos racemosa Roxb. on gonadotropin release in immature female rats and ovarian histology. J Ethnopharmacol (2004) 0.83
Mapping of equine lentivirus receptor 1 residues critical for equine infectious anemia virus envelope binding. J Virol (2007) 0.83
Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain. J Gen Virol (2005) 0.83
Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein. Biophys J (2013) 0.83
Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production. J Virol (2005) 0.82
Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection. Mol Cancer Ther (2007) 0.82
An equine infectious anemia virus variant superinfects cells through novel receptor interactions. J Virol (2008) 0.82
An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family. Retrovirology (2009) 0.81
Characterization of RNA elements that regulate gag-pol ribosomal frameshifting in equine infectious anemia virus. J Virol (2003) 0.81
Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies. Vet Microbiol (2005) 0.80
Binding of equine infectious anemia virus to the equine lentivirus receptor-1 is mediated by complex discontinuous sequences in the viral envelope gp90 protein. J Gen Virol (2008) 0.79
Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface. PLoS One (2013) 0.79
Characterization of an equine macrophage cell line: application to studies of EIAV infection. Vet Microbiol (2008) 0.79
Replication of equine infectious anemia virus in engineered mouse NIH 3T3 cells. J Virol (2008) 0.79
EQUINE INFECTIOUS ANEMIA VIRUS INFECTION AND IMMUNITY: LESSONS FOR AIDS VACCINE DEVELOPMENT. Future Virol (2011) 0.78
The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies. Vet Immunol Immunopathol (2012) 0.78
Envelope determinants of equine lentiviral vaccine protection. PLoS One (2013) 0.78
Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods (2012) 0.77
Characterization of EIAV LTR variability and compartmentalization in various reservoir tissues of long-term inapparent carrier ponies. Virology (2003) 0.77
Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41. J Biol Chem (2014) 0.76
In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile. Antimicrob Agents Chemother (2012) 0.76